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OBJECTIVES The study objectives were to determine posttransplant coronary artery disease (TxCAD)
incidence, predisposing factors and optimal timing for retransplantation (re-Tx) in pediatric
heart transplantation (Tx) recipients.
BACKGROUND The TxCAD limits long-term survival following heart Tx, with re-Tx being the primary
therapy. Information on risk factors and timing of listing for re-Tx is limited in children.
METHODS The records of children who survived .1 year post-Tx at Loma Linda University were
reviewed. Nonimmune and immune risk factors were analyzed.
RESULTS TxCAD was documented in 24 of 210 children. Freedom from TxCAD was 92 6 2% and
75 6 5% at 5 and 10 years’ post-Tx, respectively. The TxCAD diagnosis was established at
autopsy in 10 asymptomatic patients who died suddenly within nine months following the
most recent negative angiograms. The remaining 14 children had angiographic diagnoses of
TxCAD and had symptoms and/or graft dysfunction (n 5 10) or positive stress studies (n 5
4). Three of 14 died within three months after the diagnosis was made. Eleven patients
underwent re-Tx within seven months of diagnosis; nine survived. Univariate and multivar-
iate analyses showed that only late rejection (.1 year posttransplant) frequency (p 5 0.025)
and severity (hemodynamically compromising) (p , 0.01) were independent predictors of
TxCAD development. Freedom from TxCAD after severe late rejection was 78 6 8% one
year postevent and 55 6 10% by two years.
CONCLUSIONS Late rejection is an independent predictor of TxCAD. Patients suffering severe late rejection
develop angiographically apparent TxCAD rapidly and must be monitored aggressively. Both
TxCAD mortality and morbidity occur early; therefore, we recommend immediate listing for
re-Tx upon diagnosis. (J Am Coll Cardiol 2001;37:243–50) © 2001 by the American
College of Cardiology
Posttransplant coronary artery disease (TxCAD) is one of
the leading factors limiting long-term graft and patient
survival following heart transplantation (Tx) (1,2). Thera-
peutic options are primarily limited to retransplantation
(re-Tx) (3). Information regarding the course of TxCAD
once diagnosed—and therefore timing of re-Tx—is largely
lacking in the pediatric population. The perceived TxCAD
incidence in our pediatric recipients was low (4%) at five
years’ post-Tx as reported by Bailey et al. in 1995 (4).
However, with continued follow-up of those patients, a
higher incidence of TxCAD was noted, prompting reeval-
uation of the extent and scope of the disease. The objectives
of this study were to determine the incidence, predisposing
risk factors and clinical course of TxCAD for pediatric heart
transplant recipients and to identify optimal timing for
re-Tx.
METHODS
The medical records of children (,18 years) transplanted at
Loma Linda University who had survived more than one
year after Tx were retrospectively reviewed. Patients were
excluded if follow-up data were not available. The study
period encompassed November 1985 through April 1998.
All patients had selective coronary angiography using Jud-
kins catheters appropriate for size and standard techniques.
Nitroglycerin was not routinely used and was only given if
coronary artery spasm was suspected. Serial cine films were
reviewed by a panel of pediatric cardiologists, cardiothoracic
surgeons and an adult cardiologist and were compared for
local or diffuse vessel irregularities, loss of third-order
branching, vessel pruning and presence of myocardial bridg-
ing. Angiographically significant TxCAD was defined as
the presence of .50% luminal reduction whether local or
diffuse. Pathologic examination was performed in all cases
but two. On pathological examination, TxCAD was con-
sidered moderate if intimal proliferation caused .50%
luminal reduction and severe if there was .75% luminal loss
in any coronary artery branch.
Nonimmune risk factors studied included age at Tx,
gender, pre-Tx diagnosis, length of follow-up, graft isch-
emic time, cytomegalovirus (CMV) infection (defined as
new onset of clinical symptoms of CMV accompanied by
seroconversion), number of serious infections, lipid profile
and donor/recipient weight ratio, age difference, gender and
race mismatch. Immune risk factors studied were level of
immunosuppression (i.e., monotherapy vs. double immuno-
suppression) and rejection history.
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Rejection was defined as any event requiring augmenta-
tion of immunosuppression. Events precipitating such aug-
mentation included one or more of the following: 1)
endomyocardial biopsy grade $III; 2) acute echocardio-
graphic changes of rejection; and/or 3) clinical symptoms
and signs of rejection. Echocardiographic changes of rejec-
tion as previously described by this institution are increased
myocardial wall thickness with resulting increased left ven-
tricular mass and decreased volume, depressed systolic
function and new onset of mitral regurgitation (5). Asymp-
tomatic patients with biopsy grade $III on routine annual
biopsy were treated for rejection.
Rejection history was expressed as linearized rejection
rates (rejections per patient-month) for the following
post-Tx intervals: first six months, .6 to 12 months and
late rejection frequency (frequency of rejections .1 year
post-Tx per patient-month). Previously undiagnosed rejec-
tion detected only upon postmortem examination was not
classified as a rejection event and was excluded from
statistical analysis. Severe late rejection was defined as
rejection episodes that took place .1 year post-Tx and were
characterized by hemodynamic compromise accompanied
by moderate to severe echocardiographic evidence of graft
dysfunction. Hemodynamic compromise was defined if the
child 1) required inotropic support for maintenance of
cardiac output, 2) had congestive heart failure, or 3) re-
quired mechanical ventilation for pulmonary edema.
Data collected to identify the clinical course of TxCAD
included interval from diagnosis to re-Tx or death, any
intervening symptoms or cardiac events and outcome fol-
lowing re-Tx.
Immunosuppression and Rejection Treatment Protocols
Primary transplant. Cyclosporine and methylprednisolone
boluses were used for induction as well as cytolytic antibody
therapy if the Tx took place beyond the neonatal period. A
combination of cyclosporine and azathioprine (1 mg/kg)
was used as maintenance therapy. Target cyclosporine levels
were initially 250 to 300 ng/ml, gradually lowered to 100 to
150 ng/ml by the end of the first year post-Tx. Fluorescence
polarization immunoassay (FPIA) was the preferred cyclo-
sporine assay method. Steroids were not used as routine
immunosuppression. In our early experience, azathioprine
was discontinued at the end of the first year if the recipient
was a neonate (#30 days of age) at Tx and was free of
significant episodes of rejection. However, all but 16 chil-
dren were eventually restarted on azathioprine because of
rejection or renal insufficiency. Patients were not routinely
placed on calcium channel blockers or angiotensin-
converting enzyme inhibitors.
All rejection episodes were treated with intravenous (IV)
methylprednisolone (20 mg/kg/dose) given twice daily for
eight doses. Recurring or persistent rejection was reversed
by use of rabbit-derived thymogobulin or equine-derived
antithymocyte globulin antibody therapy and repeat IV
steroids. Recalcitrant rejection was treated with a variable
combination of methotrexate, conversion to tacrolimus or
total lymphoid irradiation.
Retransplantation. While awaiting re-Tx, candidates were
pretreated with high-dose (2 gm/kg) IV immunoglobulin
(IVIG) every four weeks for three doses if there was
significant elevation of percent reactive antibody titers. The
induction protocol was not different from primary Tx. For
maintenance therapy, cyclosporine levels were maintained at
200 to 250 ng/ml, and either methotrexate or mycopheno-
late mofetil was used in place of azathioprine.
Rejection surveillance protocol. Rejection surveillance
was achieved using clinical evaluation by the transplant
physicians, echocardiography and endomyocardial biopsy.
The frequency of Tx clinic visits was twice per week for the
first six weeks, then less often if free of rejection. Echocar-
diography frequency was three times per week for the first
two weeks’ post-Tx, then twice a week for the next four
weeks, decreasing to once a month for one year and finally
once every three months thereafter. Endomyocardial biopsy
schedule was according to age at Tx. Recipients below two
years at Tx had annual biopsies only. Recipients between
two and eight years at Tx had biopsy at 1 month, 3 months
and 12 months’ post-Tx and annually thereafter. Recipients
$9 years at primary Tx or following re-Tx were routinely
biopsied at 1 month, 2 months, 3 months, 6 months, 12
months and annually thereafter.
Coronary artery disease surveillance protocol. Before
1994, coronary angiography was performed every two years
and was the only testing modality for TxCAD. This was
believed to be adequate given the perceived low incidence of
TxCAD at that time. However, the diagnosis of new cases
of TxCAD in 1994 and 1995 heightened awareness of the
problem. After 1994, the protocol was changed to annual
coronary angiography, annual dobutamine stress echocardi-
ography (DSE) for children .3 years old and annual
exercise electrocardiogram (ECG) for children .6 years.
The DSE protocol used in this population is detailed in a
separate article and has a reported sensitivity of 72% and
specificity of 80% when compared to angiography (6).
Patients with suspected mild abnormalities on coronary
angiography or positive DSE underwent biannual coronary
angiography. After a severe late rejection episode, children
were monitored with coronary angiography two months
after the event; if negative, angiography was repeated at six
months and then at increasing intervals thereafter.
Statistical analysis. Univariate analysis was performed
with independent Student t-test for parametric continuous
Abbreviations and Acronyms
CMV 5 cytomegalovirus
DSE 5 dobutamine stress echocardiography
ECG 5 electrocardiogram/electrocardiographic
re-Tx 5 retransplantation
Tx 5 transplantation
TxCAD 5 posttransplant coronary artery disease
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variables and with chi-square test for nominal data. Non-
parametric data were expressed as median and range and
analyzed using the Mann-Whitney U-test. A multiple
logistic regression model was used to test variables that
reached statistical significance with univariate analysis.
Kaplan-Meier survival analysis was used to estimate free-
dom from TxCAD. The variability of these estimates is
indicated by 6 1 SEM (standard error of the mean).
RESULTS
During the study period, 313 children were transplanted;
234 survived .1 year. Twenty-four of the 234 survivors
were excluded for lack of follow-up data; the remaining 210
Tx recipients constituted the study group. Median age at Tx
was 57 days (range, 1 day to 15.5 years) and mean follow-up
period was 69 6 28 months, with 110 children having .5
years’ follow-up. Of the 210 patients, 24 had TxCAD
documented by coronary angiography and/or pathological
examination. Twelve of 14 children diagnosed with angio-
graphically significant TxCAD (.50% luminal reduction)
were confirmed to have moderate to severe TxCAD by
pathological evaluation. Two families declined the perfor-
mance of an autopsy.
Incidence of TxCAD. Freedom from significant TxCAD
at 3, 5, and 10 years’ post-Tx was 97 6 1%, 92 6 2%, and
75 6 5%, respectively; milder disease may have been missed
(Fig. 1). TxCAD alone accounted for 17% of all late deaths
(.1 year post-Tx); an additional 14% had a combination of
cellular rejection and TxCAD (total of 31%).
Clinical status and outcome for TxCAD patients. Of the
24 patients with TxCAD, 10 died suddenly with no
diagnosis of TxCAD until autopsy. The clinical information
on the 10 patients with TxCAD who died suddenly is
summarized in Table 1. Nine of these patients (90%) had
negative angiograms only three to nine months before their
deaths. None had symptoms indicative of myocardial isch-
emia before death. Autopsy examination showed moderate
rejection in 6 of 10 patients (60%) that may have contrib-
uted to their death.
The remaining 14 children had angiographic diagnosis of
TxCAD. Three of 14 children died and 11 underwent
re-Tx. The clinical information on the 14 patients with
TxCAD who were diagnosed with angiography is summa-
rized in Table 2. Coronary angiography was performed
because of symptoms in three patients (bradycardia, syncope
and congestive heart failure). Indications for coronary an-
giography in the remaining patients included routine annual
coronary angiogram (n 5 4), follow-up following severe late
rejection (n 5 5) and positive exercise ECG (n 5 1) and
positive DSE (n 5 1).
Three patients died suddenly 10 days to 3 months after
the angiographic diagnosis was made. Ten of 14 patients
had systolic 6 diastolic graft dysfunction and/or were
symptomatic. Four asymptomatic patients free of graft
dysfunction had evidence of ischemia on performing DSE
(n 5 2), exercise stress echocardiography (n 5 1) and
exercise ECG (n 5 1). Hemodynamic data at the time of
TxCAD diagnosis were normal except for three patients
who had elevated (.15 mm Hg) left ventricular end-
diastolic pressures and low cardiac output (,3.0 liter/min/
m2). Overall, 42% of TxCAD patients were asymptomatic
but died suddenly within nine months of the most recent
Figure 1. Freedom from post-Tx coronary artery disease (TxCAD). Time zero indicates date of transplant.
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angiogram, 42% had symptoms and/or graft dysfunction at
diagnosis, and 16% were asymptomatic but had positive
stress studies.
Ten of the children underwent re-Tx between five days
and seven months following diagnosis (median, 3 months).
One of our earliest cases diagnosed with TxCAD did not
undergo re-Tx until two years after diagnosis when progres-
sive graft dysfunction and worsening congestive heart failure
prompted listing for re-Tx. The child who waited seven
months before re-Tx had progressive congestive heart fail-
ure symptoms, graft dysfunction and eventually hemody-
namic instability requiring inotropic support.
Analysis for nonimmune predisposing risk factors. Uni-
variate analysis of gender, pre-Tx diagnosis, length of
follow-up, graft ischemic time, number of serious infections,
lipid profile, CMV infection, donor/recipient weight ratio,
gender mismatch, and age difference did not show any
significant predisposing factors for the development of
TxCAD (Table 3). Statistical significance was reached (p 5
0.034) for donor/recipient race mismatch, which was more
prevalent in TxCAD-free patients (60% vs. 38%). There
was no statistical difference (p 5 0.07) in the incidence of
TxCAD between neonatal recipients and older children
(Fig. 2). A comparison of patients with and without
angiographic TxCAD diagnosis in regards to age at Tx,
length of follow-up, year of Tx, type of CAD and incidence
of rejection yields no significant differences.
Analysis for immune risk factors. Univariate comparison
of monotherapy versus double immunosuppression was not
statistically significant for development of TxCAD. Univar-
iate analysis for rejection (Table 4) shows that rejection
frequency in the first six months’ post-Tx did not reach
statistical significance. However, rejection frequency in the
latter half of the first post-Tx year and late rejection
frequency were significant at p 5 0.01 and p 5 0.0001,
respectively. Overall, 67% of all patients were free of
Table 1. Clinical Data on 10 Patients With Transplant Coronary Artery Disease Who Died Suddenly With No Prior Diagnosis
Patient Gender
Age at Tx
(month)
Follow-up
(yrs)
Coronary
Angiograms
Time from
Angiogram to
Death (mo)
Percent Narrowing of
Epicardial Coronary Arteries
on Autopsy
Cellular
Rejection
on Autopsy
1 F 3 1.1 Normal 4 RCA and LAD .75% None
2 F 4 5.3 Normal 5 RCA, LAD and CX .50% None
3 F 3.5 3.0 Normal 6 RCA, LAD and CX .75% None
4 F 36 5.0 Normal 9 RCA, LAD and CX .50% None
5 M 1 2.5 Normal 3 RCA, LAD and CX .80% Moderate
6 M 0.5 1.1 Not done — RCA and CX .75%
LAD .50%
Moderate
7 M 1.5 3.8 Normal 10 RCA, LAD and CX 50–70% Moderate
8 F 36 3.4 Normal 4 RCA, LAD and CX .50% Moderate
9 M 132 3.0 Normal 26 RCA, LAD and CX .75% Moderate
10 F 1 4.2 Normal 2 RCA, LAD and CX .50% Moderate
CX 5 circumflex artery; LAD 5 left anterior descending coronary artery; RCA 5 right coronary artery; Tx 5 transplantation.
Table 2. Clinical Data on 14 Patients With Angiographic Diagnosis of Transplant Coronary Artery Disease
Patient Gender
Tx
Age
(mo)
Follow-up
(yr)
RCA
Disease by
Angiogram
LCA
Disease by
Angiogram Symptoms/Findings
Mo. to
re-Tx/Death
Percent Narrowing of
Epicardial Coronary Arteries on
Autopsy/Comments
1 F 1 4.9 Diffuse Diffuse Graft dysfunction, sudden death 2 Autopsy declined
2 M 3 6.5 Diffuse Diffuse Syncope, MI and death 3 RCA and LAD .75%;
CX occluded; recent MI
3 M 0.6 5.3 Obliteration .75% LAD Positive exercise stress
echocardiography
3 RCA, LAD and CX 5 90%
4 F 3.5 9.1 Local
.50%
Diffuse Graft dysfunction 24 RCA, LAD and CX 5 90%
5 F 0.5 6.8 Diffuse Diffuse Positive exercise stress test 3 LAD, CX and PDA .80%;
RCA .50%
6 M 0.5 7.0 Diffuse Diffuse Syncope 0.17 RCA, LAD and CX .75%
7 M 2 2.0 Diffuse Diffuse Graft dysfunction 4 RCA, LAD and CX .75%
8 M 75 3.7 Diffuse Diffuse Graft dysfunction, sudden death 0.33 Autopsy declined
9 M 24 4.3 Diffuse Diffuse Bradycardia 0.17 RCA, LAD and CX .90%
10 M 2 4.5 Diffuse Diffuse Graft dysfunction 1.5 RCA, LAD and CX .75%
11 M 46 4.4 Diffuse Diffuse Positive DSE 2.5 RCA, LAD and CX .75%
12 M 4 7.6 Obliteration LAD
obliterated
Severe graft dysfunction 1.5 RCA occluded, LAD 5 90%,
CX .50%; recent MI
13 M 28 3.5 Diffuse Diffuse Graft dysfunction 7 RCA, LAD and CX .75%
14 F 0.6 7.5 Diffuse Diffuse positive DSE 2.5 RCA and LAD .50%; recent MI
DSE 5 dobutamine stress echocardiogram; LAD 5 left anterior descending artery; LCA 5 left coronary artery; MI 5 myocardial infarction; RCA 5 right coronary artery; Tx 5
transplant.
246 Mulla et al. JACC Vol. 37, No. 1, 2001
Late Rejection as Predictor of Transplant Vasculopathy January 2001:243–50
rejection after the first post-Tx year, whereas 33% had one
or more episodes of late rejection. A history of severe late
rejection episodes was present in 48% of TxCAD patients
compared to only 10% of patients without TxCAD (p ,
0.0001).
Multiple logistic regression shows that late rejection
frequency (p 5 0.025) and severe late rejection episodes
(p , 0.01) were independent predictors of TxCAD. The
odds ratio and 95% confidence interval for development of
TxCAD in the presence of $1 late rejections were 3.95
(1.11, 14.00). The odds ratio (OR) and 95% confidence
interval (CI) for development of TxCAD after episode(s) of
severe late rejection were 4.19 (1.40, 12.54). The develop-
ment of TxCAD in the subgroup that suffered episodes of
severe late rejection was rapid (Fig. 3) with freedom from
TxCAD being 78 6 8% one year following the event and
55 6 10% by two years. Freedom from TxCAD after the
first late rejection (regardless of severity) (Fig. 4) was 94 6
3% at one year, 73 6 6% at three years and 62 6 8% by five
years.
Re-Tx outcome. Eleven patients have undergone re-Tx for
TxCAD. Early in our experience, one patient died one
month after re-Tx owing to rejection. Another patient
developed aplastic anemia in the first month following
re-Tx and died. Nine have survived, with a median
follow-up period of 37 months (range, 17 to 63 months).
Figure 2. Freedom from post-Tx coronary artery disease (TxCAD) for neonatal transplant recipients versus older infants and children. Time zero indicates
date of transplantation.
Table 3. Results of Demographic Risk Factors for Transplant
Coronary Artery Disease
Nonparametric Data: Given as Median (Range) or Proportions
Risk Factor TxCAD Control p Value
Gender 10 F, 14 M 73 F, 113 M NS
Age at Tx (days) 90 (14–4352) 51 (1–5,750) NS
D:R race mismatch 38% 60% 0.034
D:R gender mismatch 33% 50% NS
D:R age difference (yr) 0.7 (0–26) 0.4 (0–23) NS
No. of serious infections 3 (0–13) 2 (0–15) NS
CMV infection 33% 21% NS
Pretransplant diagnosis:
HLHS/variants 48% 50% NS
Complex CHD 39% 29% NS
Cardiomyopathy 13% 21% NS
Parametric Data: Given as Mean 6 SD
Follow-up (mo) 86 6 24 64 6 27 NS
Ischemic time (min) 241 6 117 267 6 118 NS
D:R weight ratio 1.8 6 0.6 1.7 6 0.7 NS
Cholesterol (mmol/liter) 153 6 45 149 6 38 NS
Triglyceride (mmol/liter) 115 6 92 92 6 81 NS
HDL (mmol/liter) 35 6 17 37 6 10 NS
LDL (mmol/liter) 104 6 47 104 6 37 NS
CX 5 Circumflex artery; LAD 5 left anterior descending coronary artery; RCA 5
right coronary artery; Tx 5 transplantation.
Table 4. Rejection Frequency Following Transplantation in
Patients With and Without Transplant Coronary Artery Disease
Rejection Frequency
(Rejections/pt. mo)
TxCAD
Present
(Mean 6 SD)
TxCAD-Free
(Mean 6 SD) p Value
First 6 mo. post-Tx 0.35 6 0.31 0.25 6 0.24 0.16
.6–12 mo. post-Tx 0.1 6 0.17 0.04 6 0.14 0.011
Late rejection frequency
(.1 yr post-Tx)
0.024 6 0.02 0.014 6 0.03 0.0001
Tx 5 transplantation.
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The median number of rejections and infections was 1
(range 0 to 4) and 1 (range 0 to 5), respectively.
DISCUSSION
TxCAD Incidence
Reports of TxCAD incidence in pediatric transplant recip-
ients have varied widely by source and time of publication.
Earlier reports indicated a high incidence of 27% to 35%
over mean follow-up periods of three years (1,7,8). Later
studies reported a lower incidence of 2% to 8% at two to
four years’ post-Tx (4,9,10). A recent study reported a 19%
incidence among 68 pediatric recipients who survived .5
years (11). Most likely, the proportion of children with
TxCAD is relative to follow-up duration. In this study the
incidence of TxCAD was 8% and 25% by 5 and 10 years’
post-Tx. This is a higher incidence than previously per-
ceived, probably due to the longer follow-up period (mean,
5.8 years) in this study. The contribution of TxCAD to late
deaths has been high. Pahl et al. (10) reported 37% of all late
deaths to be due to TxCAD. In the present study, TxCAD
contributed to 31% of all deaths occurring more than one
year post-Tx.
TxCAD Diagnosis
The characteristic pathology of TxCAD involves diffuse
concentric intimal thickening, which makes coronary an-
giography an insensitive tool because uniform luminal
reduction may not be apparent until it becomes severe. The
present study concurs with prior reports of angiographic
insensitivity (9,10,12,13).
Predisposing Risk Factors
Nonimmune risk factors. Pediatric transplant literature
has not shown any correlation of TxCAD with nonimmune
risk factors. The power of this study, at current sample size,
is ,50% for each of the risk factors examined. In this study,
the association of donor/recipient race mismatch with Tx-
CAD (less mismatch in TxCAD patients) is unexplained.
Immune risk factors. The present study supports the
earlier findings by Addonizio et al. (7), who described a
greater number of late rejections in nine children with late
graft loss. Pathological examination of eight of these grafts
showed rejection only in two and a combination of rejection
plus coronary artery disease in six. Noncompliance was
believed to have an important role in late graft loss (14).
Only late rejection history predicted TxCAD in the
present study. Both the frequency and the severity of late
rejections were significant. Frequent late rejections (regard-
less of severity) and severe late rejection episodes (even if no
other rejections existed) were independent predictors of
TxCAD development. Noncompliance may contribute to
episodes of significant late rejection; however, documenta-
tion of noncompliance has been very difficult. If indeed late
acute rejection episodes relate to periods of subtherapeutic
cyclosporine levels, then the importance of dual immuno-
regulation cannot be overstressed.
The time interval between severe late rejection episodes
and the ability to detect TxCAD angiographically is rela-
tively brief. Freedom from angiographic coronary artery
disease was only 55% by two years following severe late
rejection. Rigorous surveillance is needed to avoid sudden
death from TxCAD, which has occurred as early as two
months following the rejection event in those children.
Figure 3. Freedom from post-Tx coronary artery disease (TxCAD) following severe late rejection. Time zero refers to date of the rejection event.
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Optimal Timing for Retransplantation
Transplant coronary artery disease mortality is high, with
many of the deaths occurring suddenly. The multicenter
study compiled by Pahl and colleagues (10) reports only 9 of
58 TxCAD patients surviving, including 5 who underwent
re-Tx. Many of the deaths were sudden and unexpected
(10). In the present study, 13 of 24 (54%) TxCAD patients
died suddenly, and 2 died following re-Tx. Overall, only 9
of 24 (37%) patients with TxCAD survived, all after re-Tx.
Sudden death occurred within a relatively short time (3 to 9
months) for those with negative angiograms and 10 days to
3 months for those with positive coronary angiography. It
remains to be seen whether the sudden death incidence will
be decreased with heightened surveillance protocols and
identification of high-risk children. TxCAD morbidity,
manifesting as bradycardia, syncope, graft dysfunction and
congestive heart failure, is also high.
Re-Tx is the only documented therapeutic option of
long-term benefit in children (3,15). In the face of high
TxCAD mortality/morbidity and lengthy waiting periods
for donor organs, we recommend immediate listing for
re-Tx upon establishing a diagnosis of TxCAD. There is no
advantage to waiting until a child shows evidence of graft
dysfunction or symptoms of myocardial ischemia secondary
to TxCAD. In the absence of angina, symptomatic moni-
toring of ischemia is not reliable; hence, the first manifes-
tation may be sudden death.
Retransplantation Outcome
The outcome following re-Tx has been encouraging thus
far. This is consistent with reports of improved outcome of
elective re-Tx for CAD compared with that for acute re-Tx
required for graft failure/rejection (16–18). These studies
report no difference in rejection and infection rates when
compared to primary Tx. The duration of follow-up for the
present cohort of re-Txs is inadequate to evaluate long-term
mortality and morbidity.
Prevention
The question of whether increased immunosuppression
decreases the incidence of TxCAD was addressed in a study
by Addonizio et al. (9), who reported a drop in TxCAD
incidence from 18% to 2% by going from double to triple
immunosuppression (both groups were on maintenance
steroid therapy). However, reports on steroid therapy re-
main divided. Braunlin and colleagues (8) reported a 35%
incidence of TxCAD in children receiving triple immuno-
suppression. Other investigators found that a higher pred-
nisone dose was substantially deleterious, and some adult
centers are now moving away from maintenance steroid
therapy (19,20). The effect of steroid therapy on TxCAD
could not be tested in the present study as steroids are
primarily used for acute rejection therapy and not for
routine maintenance therapy and hence cannot be statisti-
cally separated from the rejection event.
The perceived benefits of routine triple immunosuppres-
sion must be weighed against the risks of infection and
neoplasia. Increasing immunosuppression for all recipients
would mean that the 67% of children in the present study
who never experienced late rejection would be exposed to
unnecessary growth impairment, infections, and neoplastic
risks.
Figure 4. Freedom from post-Tx coronary artery disease (TxCAD) following first episode of late rejection. Time zero refers to date of first late rejection.
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Conclusions. Finally, late rejection is an independent pre-
dictor of TxCAD. The most rapid angiographic develop-
ment of TxCAD will follow episodes of severe (hemody-
namically compromising) late rejection. The morbidity and
mortality of TxCAD are high and occur early. Successful
re-Tx has improved TxCAD survival. We therefore recom-
mend rigorous screening for TxCAD especially after epi-
sodes of severe late rejection and immediate listing for re-Tx
upon diagnosis. Further studies centering on CAD preven-
tion are needed.
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